Article Top Ad
Reading Time: 3 minutes

 

Phillips-Medisize, a Molex company and a leader in the development and manufacture of drugs, diagnostics, and MedTech devices, announces the expansion of its global manufacturing footprint, along with extended product design, development and manufacturing capabilities to streamline the delivery of breakthrough products and solutions. The company’s global reach now includes 36 world-class facilities with scalable, end-to-end capabilities tailored to help customers bring groundbreaking products to market quickly and efficiently from anywhere in the world.

“As the preferred partner for leading global customers, we continually invest in new talent and technologies that increase the capacity and capabilities of Phillips-Medisize across the entire value chain,” stated Paul Chaffin, president, Medical and Pharmaceutical Solutions, Molex. “Our expanded global reach and resources will enable us to solve complex development and manufacturing challenges while meeting escalating customer demands for more localized production, supply chain management and accelerated go-to-market strategies.”

Growing Footprint for Local Support, Global Scale

To meet growing manufacturing demand from customers in continental Europe, Phillips-Medisize is building a state-of-the-art medical manufacturing facility in Katowice, Poland. The site, scheduled to open in 2022, will complement production sites and innovation centers in Asia, Europe, India, Mexico, and North America. Phillips-Medisize is also expanding its manufacturing capacity in Suzhou, China to serve both global and regional pharmaceutical and MedTech customers. In addition, the transformation of an existing Molex production facility in Little Rock, Ark, is underway, enabling Phillips-Medisize to keep pace with the ever-increasing demands in the U.S. for high-volume diagnostic device manufacturing.

Once these expansions are complete, Phillips-Medisize will offer nearly three million square feet/280,000 square meters of the country- and region-specific manufacturing space and R&D capacity worldwide. The company will also provide 600,000 square feet/ 55,000 square meters of Class 7 and Class 8 cleanrooms to complement its existing tooling and global quality and regulatory systems locations. In 2020, Phillips-Medisize completed a new 26,000-square-foot facility in St. Croix Meadows, Wisconsin, to support the production of molded parts for medical diagnostic customers requiring high-volume assembly and packaging of regulated products. The facility also includes a nearly 64,000 square foot/6,000 square-meter ISO 14644-1 Class 8 cleanroom.

Extending End-to-End Capabilities

Phillips-Medisize provides single-source medical device manufacturing solutions, focusing on design for manufacturability and assembly excellence. Proven front-end innovation, human-factors engineering, and quality are combined with regulatory adherence to reduce go-to-market risk and cost. Advanced capabilities in complex molding, drug and reagent handling, and final packaging and serialization enable customers to consolidate their global supply chains while optimizing their go-to-market strategies.

Phillips-Medisize’s combined expertise in plastics, metals, electronics, and connectivity ease the development of various solutions, including combination devices such as needle-based injection systems and wearable injection technologies. An unwavering commitment to rigorous quality management is reinforced by dedicated New Product Introduction (NPI) teams at each site. Strategic investments in talent acquisition to support Phillips-Medisize’s continued growth are expected to add at least 1,000 employees globally over the next couple of years.

Optimization Of Industry-Leading Collaborations

A strong track record of collaboration ensures Phillips-Medisize is at the forefront of the latest advancements in drug delivery, diagnostic, and MedTech devices. Today, Credence MedSystems announced a strategic initiative with Phillips-Medisize that includes ramping production of the Credence Companion® and Dual Chamber Reconstitution Systems at the Phillips-Medisize Letterkenny, Ireland site and the new facility in Poland.

“We’re excited to leverage Phillips-Medisize’s world-class manufacturing as we scale toward high-volume automation at the new state-of-the-art facility in Poland,” expressed the COO at Credence MedSystems, Jeff Tillack. “The opportunity to scale production in close proximity to our operations and European customers will accelerate market delivery of our innovative solutions to meet the needs of our pharma customers and their end-users.”

In September, GlucoModicum completed a design and development program with Phillips-Medisize to rapidly expand manufacturing of its Talisman needle-free continuous glucose monitoring device, which uses unique magnetohydrodynamic (MHD) technology. Also last month, Paris-based Eyevensys announced a collaboration with Phillips-Medisize to optimize the design, development, and high-volume manufacturing of its ocular device component that powers the delivery of novel gene therapies to treat various eye diseases.